Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DONALD S LEVY

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1518055011
CMS profile
294997
Location
ORANGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$42,333.93

154 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DONALD S LEVY

NPI 1518055011 · CMS profile ID 294997

Allopathic & Osteopathic Physicians / Allergy & Immunology

ORANGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518055011?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DONALD S LEVY, NPI 1518055011, CMS profile ID 294997. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518055011?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). DONALD S LEVY, NPI 1518055011, CMS profile ID 294997. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518055011?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
DONALD S LEVY, NPI 1518055011, CMS profile ID 294997, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1518055011?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

154 matching records · $42,333.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 154 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 154.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Teva Pharmaceuticals USA, Inc. $15.4504/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697705981 CMS
PFIZER INC. $17.0404/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671961771 CMS
CSL Behring $117.9304/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840387 CMS
GlaxoSmithKline, LLC. $3.0004/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670817987 CMS
AstraZeneca Pharmaceuticals LP $12.4004/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685509881 CMS
AstraZeneca Pharmaceuticals LP $29.1404/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685787771 CMS
BioCryst Pharmaceuticals, Inc. $28.3304/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702238887 CMS
BioCryst Pharmaceuticals, Inc. $10.8604/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702238891 CMS
BioCryst Pharmaceuticals, Inc. $47.2204/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702238895 CMS
BioCryst Pharmaceuticals, Inc. $10.8304/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702238899 CMS
BioCryst Pharmaceuticals, Inc. $315.2704/13/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702238917 CMS
BioCryst Pharmaceuticals, Inc. $121.1104/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702238881 CMS
BioCryst Pharmaceuticals, Inc. $303.9704/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702238903 CMS
BioCryst Pharmaceuticals, Inc. $599.6004/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702238907 CMS
CSL Behring $7.6903/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840353 CMS
PFIZER INC. $17.9003/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671907265 CMS
AstraZeneca Pharmaceuticals LP $13.6503/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685469009 CMS
GlaxoSmithKline, LLC. $18.1403/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670619489 CMS
OptiNose US, Inc. $11.2703/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684241213 CMS
CSL Behring $40.9403/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840273 CMS
ALK-Abello, Inc $13.1503/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698047353 CMS
PFIZER INC. $20.4302/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671889161 CMS
CSL Behring $88.0702/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840253 CMS
CSL Behring $95.1902/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840251 CMS
CSL Behring $29.0002/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840377 CMS
CSL Behring $58.0002/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840379 CMS
CSL Behring $398.2502/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840381 CMS
CSL Behring $1,560.0002/22/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840383 CMS
CSL Behring $74.7602/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840385 CMS
GlaxoSmithKline, LLC. $3.9002/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671536541 CMS
Shire North American Group Inc $66.4002/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637864859 CMS
AstraZeneca Pharmaceuticals LP $16.0702/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685251339 CMS
CSL Behring $2,590.0002/11/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840365 CMS
CSL Behring $260.5402/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840367 CMS
CSL Behring $303.7702/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840369 CMS
CSL Behring $369.6102/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840371 CMS
CSL Behring $386.2802/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840373 CMS
CSL Behring $89.2102/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840255 CMS
AstraZeneca Pharmaceuticals LP $13.3202/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685514331 CMS
CSL Behring $12.0701/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840257 CMS
CSL Behring $85.9001/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840237 CMS
CSL Behring $59.0201/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840235 CMS
CSL Behring $26.4001/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840239 CMS
GlaxoSmithKline, LLC. $5.7801/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670347687 CMS
CSL Behring $73.8401/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840243 CMS
Shire North American Group Inc $109.5401/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637864855 CMS
Shire North American Group Inc $15.4501/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637864857 CMS
Shire North American Group Inc $13.8501/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 637864853 CMS
CSL Behring $25.7801/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683840241 CMS
PFIZER INC. $22.4101/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671857977 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $42,333.93 154
PY2020 $15,458.84 55
PY2021 $20,217.50 144
PY2022 $14,106.65 149
PY2023 $17,976.04 204
PY2024 $58,982.52 207
PY2025 $37,661.49 182

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $22,195.65 9
PY2025 Principal investigator $2,706.50 2
PY2024 Recipient $25,834.69 12
PY2023 Recipient $29,401.06 3
PY2023 Principal investigator $5,275.73 9
PY2022 Principal investigator $14,493.37 23
PY2021 Recipient $39,000.00 1
PY2021 Principal investigator $21,521.31 18
PY2020 Recipient $719.25 15
PY2020 Principal investigator $8,237.38 11
PY2019 Principal investigator $29,497.53 52

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

11 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient CSL Behring $281.00 10/22/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664867
Recipient CSL Behring $3,656.17 10/14/2025 Covered Recipient Physician A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252664861
Recipient CSL Behring $6,083.42 08/13/2025 Covered Recipient Physician A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252664859
Recipient CSL Behring $116.16 07/23/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664855
Recipient CSL Behring $1,700.00 07/16/2025 Covered Recipient Physician A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252664865
Recipient CSL Behring $10,040.00 06/24/2025 Covered Recipient Physician A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252664857
Recipient CSL Behring $88.24 06/13/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664863
Recipient CSL Behring $117.30 06/02/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664853
Principal investigator 1 CSL Behring $203.50 05/28/2025 Non-covered Recipient Entity
Donald Levy
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673022
Principal investigator 1 CSL Behring $2,503.00 04/07/2025 Non-covered Recipient Entity
Donald Levy
A Phase 4 Open-label Study to Evaluate the Safety After Switching to CSL312 (Garadacimab) From Current Prophylactic HAE Treatment in Subjects With HAE 12 Years of Age No dispute reported 06/30/2026 1252673016
Recipient CSL Behring $113.36 01/29/2025 Covered Recipient Physician An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252664851